Adding insulin to oral antidiabetic agents early in the course of disease can help patients achieve better glucose control, but many patients will need a combined insulin regimen, investigators reported.

Diamyd Medical announced last Thursday further evidence for lasting immunologic efficacy of the Diamyd® diabetes vaccine.and showed that treatment with Diamyd® causes a specific immune response to GAD65 remaining even 15 months after treatment.

Because most patients do not understand what an A1c result means, the industry standard will now be to tell patients what their average blood glucose is.

The American College of Physicians (ACP) has issued a guidance statement on the optimal hemoglobin A1c targets for patients with type 2 diabetes. More confusion?

Even in nondiabetics, increased HbA1c levels are associated with a significantly increased risk of nonfatal cardiovascular disease after other cardiovascular risk factors are accounted for.

Type 2 diabetes patients failing to achieve recommended glycemic goals despite high doses of metformin, are four times more likely to reach recommended targets by adding the DPP-4 inhibitor vildagliptin (Galvus) to their metformin regimen. Following EU approval, Eucreas will be first single-tablet combination of a DPP-4 inhibitor and metformin …

For patients with type 2 diabetes, using a insulin pen is associated with reduced health care utilization compared with using vials and syringes, according to results of a new study. The reduced use of health care resources translates directly into cost savings.

New research, including two studies presented this week at the 43rd Annual Meeting of the European Association for the Study of Diabetes (EASD), further support the cardiovascular safety of ACTOS (pioglitazone HCI) and its benefits regarding improved blood glucose and blood lipid levels for patients with type 2 diabetes.

Preliminary research suggests that in children at increased risk for type 1 diabetes, dietary intake of omega-3 fatty acids was associated with a reduced risk of pancreatic islet autoimmunity, which is linked to the development of diabetes..

Phase 3 study confirms that liraglutide treatment leads to both glucose and weight reduction with a low risk of hypoglycaemic events Novo Nordisk today announced clinical results from the fourth of five phase 3 studies with liraglutide